Чорногорія - хорватська - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"pdg professional development group" d.o.o. podgorica - dijagnostička i terapeutska sredstva u radiologiji

Чорногорія - хорватська - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"pdg professional development group" d.o.o. podgorica - dijagnostička i terapeutska sredstva u radiologiji

Чорногорія - хорватська - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"pdg professional development group" d.o.o. podgorica - dijagnostička i terapeutska sredstva u radiologiji

Чорногорія - хорватська - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"pdg professional development group" d.o.o. podgorica - dijagnostička i terapeutska sredstva u radiologiji

Чорногорія - хорватська - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"pdg professional development group" d.o.o. podgorica - dijagnostička i terapeutska sredstva u radiologiji

Чорногорія - хорватська - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"pdg professional development group" d.o.o. podgorica - dijagnostička i terapeutska sredstva u radiologiji

Чорногорія - хорватська - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"pdg professional development group" d.o.o. podgorica - dijagnostička i terapeutska sredstva u radiologiji

Європейський Союз - хорватська - EMA (European Medicines Agency)

dynavax gmbh - hepatitis b površinski antigen - hepatitis b - cjepiva - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Європейський Союз - хорватська - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - follitropin beta - infertility; hypogonadism - spolni hormoni i modulatori genitalnog sustava, - u ženskom:fertavid indiciran za liječenje ženske neplodnosti u sljedećim kliničkim slučajevima:ановуляция (uključujući policističnih jajnika bolest, koncept пбвп), kod žena koje su ne поддающаяся liječenju s clomifene citratecontrolled hiperstimulacije jajnika za indukciju razvoj više folikula u lijekovima kopiranje programa [e-mail. in vitro oplodnje/presađivanje embrija (ivf/pe), гаметы unutar-маточную prijenosa (poklon) i интрацитоплазматическая injekcije spermija (icsi). muški:nedovoljan spermatogeneze zbog hypogonadotrophic гипогонадизм.

Європейський Союз - хорватська - EMA (European Medicines Agency)

astrazeneca ab - olaparib - neoplazme jajnika - antineoplastična sredstva - jajnika cancerlynparza prikazan kao monoterapija za:podržava liječenje odraslih bolesnika s поздними (figo faze iii i iv) u genima brca1/2-mutirani (зародышевой linije i/ili somatskih) brzorezni epitela jajnika, masterbatch cijevi ili primarni перитонеальный rak, koji u odgovor (potpuno ili djelomično) nakon završetka prve linije na bazi platine kemoterapije. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 i 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. pacijenti moraju prethodno bile tretirane s антрациклина i таксана u (neo)adjuvantne ili метастатический, ako pacijenti nisu prikladni za tih postupaka (vidi odjeljak 5. pacijenti s receptore hormona (h)-pozitivnog raka dojke treba također razvili ili nakon pre-hormonska terapija, ili se smatraju neprikladnim za endokrine terapije. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.